Zoldonat 4 mg Injection
Brand Name: Zoldonat
Molecule: Zoledronic Acid
Strength: 4 mg
Quantity: 1 Vial
Form: Injection
Packaging Type: Vial
Manufacturer/Marketed By: Natco Pharma
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
Zoldonat 4 mg Injection contains Zoledronic Acid, a highly effective bisphosphonate medication widely used in the management of bone-related complications associated with cancer and other serious medical conditions. It is commonly prescribed for patients whose cancer has spread to the bones (bone metastases), as well as those suffering from multiple myeloma and hypercalcemia of malignancy (elevated calcium levels caused by cancer). Bone complications are a major concern in advanced cancer, often leading to pain, fractures, and reduced quality of life. Zoldonat works by strengthening bones and reducing the breakdown of bone tissue, thereby helping prevent serious skeletal-related events such as fractures, spinal cord compression, and the need for radiation or surgery to bones. This injection is administered intravenously under the supervision of a healthcare professional, ensuring control
Benefits
- Helps reduce risk of bone fractures
- Controls high calcium levels in cancer patients
- Strengthens bones weakened by cancer
- Reduces bone pain and complications
- Improves quality of life in advanced cancer patients
Indications and Usage
Zoldonat 4 mg Injection is prescribed for:
- Bone metastases (cancer spread to bones)
- Multiple myeloma
- Hypercalcemia of malignancy (high calcium due to cancer)
- Osteoporosis (in some cases)
- Prevention of skeletal-related events (fractures, spinal compression)
How it Works
Zoldonat contains Zoledronic Acid, which belongs to a class of drugs called bisphosphonates.
It works by:
- Inhibiting bone resorption (breakdown of bone)
- Slowing down the activity of osteoclasts (cells that destroy bone)
- Helping maintain bone strength and density
This reduces complications caused by cancer affecting the bones.
Dosage & Administration
- Administered as an intravenous (IV) infusion
- Usually given every 3 to 4 weeks for cancer-related conditions
- Infusion duration: at least 15 minutes
- Dose adjustments may be required in kidney impairment
Must be administered by a healthcare professional only.
Side Effects
Common side effects:
- Fever
- Fatigue
- Bone or muscle pain
- Nausea
- Headache
Serious side effects:
- Kidney problems
- Low calcium levels (hypocalcemia)
- Osteonecrosis of the jaw (rare but serious)
- Irregular heartbeat
Patients should immediately consult a doctor if serious symptoms occur.
Warning and Precaution
- Monitor kidney function before each dose
- Ensure adequate hydration before treatment
- Avoid use in severe kidney disease
- Maintain proper oral hygiene to prevent jaw complications
- Not recommended during pregnancy or breastfeeding
- Calcium and Vitamin D supplementation may be required
Patient Guidance
- Follow your doctor’s schedule strictly
- Stay well hydrated before and after infusion
- Inform your doctor about dental issues before starting treatment
- Report symptoms like jaw pain, muscle cramps, or unusual fatigue
- Continue calcium and vitamin supplements if prescribed
Clinical Trial & Approvals
Zoledronic Acid has been widely studied and is approved globally for managing bone complications in cancer patients.
- Approved by regulatory authorities including the U.S. Food and Drug Administration
- Proven effective in reducing skeletal-related events in multiple cancers
- Supported by clinical studies in oncology and bone health management
References
Zoledronic acid for skeletal-related events (PubMed Study)
Study shows zoledronic acid helps reduce skeletal-related events in patients with bone metastases.
https://pubmed.ncbi.nlm.nih.gov/31673791/
Zoledronic acid vs pamidronate clinical trial (PubMed)
Demonstrates effectiveness of zoledronic acid in treating bone metastases and osteolytic lesions.
https://pubmed.ncbi.nlm.nih.gov/11283917/
European Medicines Agency (EMA) report on Zoledronic Acid
Confirms mechanism as a potent bisphosphonate inhibiting bone resorption.
https://www.ema.europa.eu/en/documents/variation-report/zometa-h-c-336-ii-0031-epar-assessment-report-variation_en.pdf
Health-economic review of Zoledronic Acid (Taylor & Francis)
Supports its role in preventing skeletal complications in cancer patients.
https://www.tandfonline.com/doi/full/10.1586/erp.12.31
Zoledronic acid clinical trial registry (ClinicalTrials.gov)
Ongoing research evaluating its efficacy in preventing bone-related events in cancer patients.
https://clinicaltrials.gov/study/NCT05480189
Zoledronic Acid Drug Information (General Overview)
Covers indications like bone metastases, osteoporosis, and hypercalcemia of malignancy.
https://en.wikipedia.org/wiki/Zoledronic_acid
FDA prescribing information for Zoledronic Acid (Reclast)
Provides safety data, adverse effects, and clinical usage guidance.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021817Orig1s012.pdf
Related Products
Related Posts:
Bone Marrow Transplant: A Complete Guide for Patients
The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may
READ MORE »June 16, 2026
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026